Wang Yucheng, Weng Jitian, Wu Qing, Wen Jiamin, Gao Qiong, Lu Wei, Tao Xiaohua, Tang Yi
Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.
The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 310053, People's Republic of China.
Infect Drug Resist. 2024 Nov 29;17:5325-5334. doi: 10.2147/IDR.S484519. eCollection 2024.
This study aimed to investigate the infection rate, types of human papillomavirus (HPV), and the relationship between HPV types and host factors in Zhejiang and lay a foundation for developing a prophylactic HPV vaccine.
A retrospective analysis of the genotyping results of 27 hPV types using exfoliated cells from the cervix, vulva, perianal region, or oral mucosa of 28206 females, and exfoliated cells from the penis, perianal region or oral mucosa of 2923 male patients undergoing treatment between January 2016 and December 2021 at Zhejiang Provincial People's Hospital was performed.
In females, the overall positive rate was 30.26%. The top five HPV types were HPV52, 58, 16, 6, and 53. In males, the overall positive rate was 31.85%. The top five HPV types were HPV6, 11, 16, 52, and 43. About 90.48% of patients with CINII+ were HR-HPV+. HPV33, 16 were the top two HPV types that increased CINII+ risks.
Currently, the bivalent (HPV16, 18), quadrivalent (HPV6, 11, 16, 18), and 9-valent (HPV6, 11, 16, 18, 31, 33, 45, 52, 58) HPV vaccines are marketed. Of these, the 9-valent HPV vaccines are more suitable for people in the Zhejiang province; however, it is still insufficient. Therefore, the 11-, 14-, and 15-valent vaccines being developed and marketed include more genotypes, and their outcomes are worth anticipating.
本研究旨在调查浙江省人乳头瘤病毒（HPV）的感染率、类型以及HPV类型与宿主因素之间的关系，为研发预防性HPV疫苗奠定基础。
对2016年1月至2021年12月期间在浙江省人民医院接受治疗的28206名女性的宫颈、外阴、肛周区域或口腔黏膜脱落细胞，以及2923名男性患者的阴茎、肛周区域或口腔黏膜脱落细胞进行27种HPV类型基因分型结果的回顾性分析。
女性总体阳性率为30.26%。HPV感染类型前五位依次为HPV52、58、16、6和53。男性总体阳性率为31.85%。HPV感染类型前五位依次为HPV6、11、16、52和43。约90.48%的CINII+患者为高危型HPV（HR-HPV）阳性。HPV33、16是增加CINII+风险的前两种HPV类型。
目前，二价（HPV16、18）、四价（HPV6、11、16、18）和九价（HPV6、11、16、18、31、33、45、52、58）HPV疫苗已上市。其中，九价HPV疫苗更适合浙江省人群；然而，仍然不足。因此，正在研发和上市的11价、14价和15价疫苗包含更多基因型，其效果值得期待。
